Campbell & CO Investment Adviser LLC Acquires Shares of 37,842 Scholar Rock Holding Co. (NASDAQ:SRRK)

Campbell & CO Investment Adviser LLC acquired a new stake in Scholar Rock Holding Co. (NASDAQ:SRRKFree Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 37,842 shares of the company’s stock, valued at approximately $711,000. Campbell & CO Investment Adviser LLC owned approximately 0.05% of Scholar Rock at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank increased its stake in shares of Scholar Rock by 52.8% in the 3rd quarter. Amalgamated Bank now owns 4,217 shares of the company’s stock valued at $30,000 after purchasing an additional 1,458 shares during the last quarter. Silverarc Capital Management LLC bought a new stake in Scholar Rock during the 3rd quarter worth $69,000. State Board of Administration of Florida Retirement System bought a new stake in Scholar Rock during the 3rd quarter worth $88,000. China Universal Asset Management Co. Ltd. grew its position in Scholar Rock by 479.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,346 shares of the company’s stock worth $157,000 after acquiring an additional 6,905 shares during the last quarter. Finally, Spire Wealth Management bought a new stake in Scholar Rock during the 4th quarter worth $178,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Price Performance

SRRK stock opened at $9.51 on Friday. The stock’s 50 day simple moving average is $13.33 and its 200 day simple moving average is $15.00. Scholar Rock Holding Co. has a fifty-two week low of $5.93 and a fifty-two week high of $21.17. The company has a quick ratio of 6.58, a current ratio of 6.58 and a debt-to-equity ratio of 0.24.

Scholar Rock (NASDAQ:SRRKGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). During the same period last year, the business earned ($0.46) earnings per share. Equities research analysts forecast that Scholar Rock Holding Co. will post -2.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Raymond James started coverage on Scholar Rock in a research report on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 price objective on the stock. Truist Financial reissued a “buy” rating and issued a $20.00 price objective on shares of Scholar Rock in a research note on Wednesday, April 3rd. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Scholar Rock in a research note on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $28.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 26th. Finally, Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Scholar Rock in a research note on Tuesday, May 7th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $25.17.

Get Our Latest Stock Report on Scholar Rock

Scholar Rock Profile

(Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Recommended Stories

Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Co. (NASDAQ:SRRKFree Report).

Institutional Ownership by Quarter for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.